OT::IGF::OT A phase I single-arm, multicenter pilot study aimed at validating y-OHPdG as a biomarker and testing the effects of Polyphenon E on its levels in patients with cirrhosis

OT::IGF::OT I 期单组、多中心试点研究，旨在验证 y-OHPdG 作为生物标志物并测试 Polyphenon E 对其肝硬化患者水平的影响

• 批准号: 10329662
• 负责人: Seema Khan
• 金额: $ 14.21万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-11-06 至 2021-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10329662
• 关键词: Age; Biological Markers; Cirrhosis; Diagnosis; Hepatocarcinogenesis; Incidence; Liver; Malignant Neoplasms; Malignant neoplasm of pancreas; Patients; Phase; Pilot Projects; Polyphenon E; Primary carcinoma of the liver cells; Survival Rate; Testing; Woman; arm; men; primary endpoint

Hepatocellular carcinoma (HCC) is a lethal cancer with rising incidence and rates. In 2014, about 33,000 HCC diagnoses were expected, and the incidence is increasing among the most rapidly of any cancer, with an age-adjusted annual increase of 3.7% and 2.9% in men and women, respectively (3%). Tragically, HCC has a dismal 5-year survival rate of 18%, second in lethality only to pancreatic cancer. Hepatocarcinogenesis begins with changes in the liver architerure as reflected by various degrees of cirrhosis.

肝细胞癌是一种发病率和发病率呈上升趋势的致命性癌症。2014年，预计约有3.3万人被诊断为肝细胞癌，发病率在所有癌症中增长最快，经年龄调整后，男性和女性的年增长率分别为3.7%和2.9%(3%)。不幸的是，肝细胞癌的5年存活率只有18%，在致死率上仅次于胰腺癌。肝癌的发生始于不同程度的肝硬变所反映的肝脏结构的改变。